Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents

Korean Journal of Laboratory Medicine

Volumn 31, Issue 4, 2011, Pages 271-278

  Kim, Kyeong Hee ^a   Lee, Sung Won ^a   Chung, Won Tae ^a   Kim, Byoung Gwon ^a   Woo, Kwang Sook ^a   Han, Jin Yeong ^a   Kim, Jeong Man ^a  

^a Dong A University   (South Korea)

Author keywords

Conversion; Immunosuppressive agent; Interferon gamma release assay; Latent tuberculosis infection

Indexed keywords

GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD CELL COUNT; FEMALE; FOLLOW UP; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MALE; METABOLISM; MIDDLE AGED; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULIN TEST;

ADULT; BLOOD CELL COUNT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; TUBERCULIN TEST;

EID: 84863261704     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2011.31.4.271     Document Type: Article

References (22)

1. Small PM and Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med 2001;345:189-200. (Pubitemid 32662129)
2. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:2060-7.
3. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002;347:1860-6. (Pubitemid 35417778)
4. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax 2002;57:804-9. (Pubitemid 34984980)
5. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61. (Pubitemid 40965087)
6. U.S. Food and Drug Administration, (Eds.), T-SPOT-TB - P070006. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num= P070006 (Updated on Jul 2008).
7. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB gold test for detecting mycobacterium tuberculosis infection, United States MMWR Recomm Rep 2005;54:49-55.
8. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010;59:1-25.
9. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
10. Korea Food and Drug Administration. Guideline for diagnosis and treatment of latent tuberculosis infection in patients treated with TNF blockers. Korea Food and Drug Administration, 2004.
11. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84.
12. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63.
13. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008;59:800-6.
14. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of QuantiFERON-TB gold in-tube assay. Clin Vaccine Immunol 2008;15:425-32. (Pubitemid 351967072)
15. Koh WJ, Kwon OJ, Lee KS. Diagnosis and treatment of nontuberculous mycobacterial pulmonary diseases: a Korean perspective. J Korean Med Sci 2005;20:913-25. (Pubitemid 43161852)
16. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006; 8:R114.
17. Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008;67:84-90.
18. Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2009;36:2675-81.
19. Malaviya AN, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S, et al. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - An audit report. J Rheumatol 2009;36:1414-20.
20. Shovman O, Anouk M, Vinnitsky N, Arad U, Paran D, Litinsky I, et al. QuantiFERON-TB gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis 2009;13:1427-32.
21. Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis 2006;43:1540-6. (Pubitemid 44901894)
22. Komiya K, Ariga H, Nagai H, Teramoto S, Kurashima A, Shoji S, et al. Impact of peripheral lymphocyte count on the sensitivity of 2 IFN-gamma release assays, QFT-G and ELISPOT, in patients with pulmonary tuberculosis. Intern Med 2010;49:1849-55.